SAFETY AND EFFICACY OF THE ANTI-TISSUE FACTOR PATHWAY INHIBITOR MARSTACIMAB IN PARTICIPANTS WITH SEVERE HEMOPHILIA WITHOUT INHIBITORS: RESULTS FROM THE PHASE 3 BASIS TRIAL AND ONGOING LONG-TERM EXTENSION STUDY

被引：0
|
作者：
Acharya, Suchitra S. [1 ]
Matino, Davide [2 ]
Palladino, Andrew [3 ]
Hwang, Eunhee [3 ]
McDonald, Regina [4 ]
Taylor, Carrie Turich [5 ]
Teeter, John [5 ]
机构：
[1] Northwell Hlth, Northwell Hemostasis & Thrombosis Ctr, Cohen Childrens Med Ctr, New Hyde Pk, NY USA
[2] McMaster Univ, 237 Barton St East, Hamilton, ON, Canada
[3] Pfizer Inc, Collegeville, PA USA
[4] Pfizer Inc, New York, NY USA
[5] Pfizer Inc, Groton, CT USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4 / 4
页数：1
相关论文
共 50 条
  • [41] Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
    Petersenn, Stephan
    Farrall, Andrew J.
    Block, Christophe
    Melmed, Shlomo
    Schopohl, Jochen
    Caron, Philippe
    Cuneo, Ross
    Kleinberg, David
    Colao, Annamaria
    Ruffin, Matthieu
    Resendiz, Karina Hermosillo
    Hughes, Gareth
    Hu, Ke
    Barkan, Ariel
    PITUITARY, 2014, 17 (02) : 132 - 140
  • [42] Efficacy and Safety of Switching from Adalimumab to Baricitinib: Long-Term Data from Phase 3 Extension Study in Patients with Rheumatoid Arthritis
    Weinblatt, Michael E.
    Taylor, Peter C.
    Keystone, Edward C.
    Ortmann, Robert A.
    Issa, Maher
    Xie, Li
    de Bono, Stephanie
    Tanaka, Yoshiya
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [43] Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study
    Busse, William W.
    Bleecker, Eugene R.
    Fitzgerald, J. Mark
    Ferguson, Gary T.
    Barker, Peter
    Sproule, Stephanie
    Olsson, Richard F.
    Goldman, Mitchell
    Martin, Ubaldo
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [44] BAY 81-8973 Demonstrates Long-Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study
    Ljung, Rolf
    Chan, Anthony K. C.
    Ahuja, Sanjay P.
    Mancuso, Maria Elisa
    Marquez, Jose Francisco Cabre
    Volk, Florian
    Blanchette, Victor
    Kerlin, Bryce A.
    Trakymiene, Sonata Saulyte
    Glosli, Heidi
    Kenet, Gili
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (03) : 556 - 565
  • [45] Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period
    Warren, Richard B.
    Lebwohl, Mark
    Thaci, Diamant
    Gooderham, Melinda
    Pinter, Andreas
    Paul, Carle
    Gisondi, Paolo
    Szilagyi, Balint
    White, Katy
    Deherder, Delphine
    Staelens, Fabienne
    Lambert, Jeremy
    Strober, Bruce
    BRITISH JOURNAL OF DERMATOLOGY, 2025,
  • [46] Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension
    Sinclair, Rodney
    Thaci, Diamant
    Vender, Ronald
    de Rie, Menno
    Conrad, Curdin
    Soung, Jennifer
    Strober, Bruce
    Wang, Maggie
    Cross, Nancy
    Deherder, Delphine
    Gomez, Natalie Nunez
    Gottlieb, Alice B.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 18 - 18
  • [47] Long-term efficacy and safety of osilodrostat in Cushing’s disease: final results from a Phase II study with an optional extension phase (LINC 2)
    Maria Fleseriu
    Beverly M. K. Biller
    Jérôme Bertherat
    Jacques Young
    Betul Hatipoglu
    Giorgio Arnaldi
    Paul O’Connell
    Miguel Izquierdo
    Alberto M. Pedroncelli
    Rosario Pivonello
    Pituitary, 2022, 25 : 959 - 970
  • [48] Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2)
    Fleseriu, Maria
    Biller, Beverly M. K.
    Bertherat, Jerome
    Young, Jacques
    Hatipoglu, Betul
    Arnaldi, Giorgio
    O'Connell, Paul
    Izquierdo, Miguel
    Pedroncelli, Alberto M.
    Pivonello, Rosario
    PITUITARY, 2022, 25 (06) : 959 - 970
  • [49] Long-term Efficacy and Safety of Fingolimod in Japanese Patients with Relapsing Multiple Sclerosis (MS): 3-year Results from a Phase 2 Extension Study
    Kira, J.
    Itoyama, Y.
    Kikuchi, S.
    Hao, Q.
    Kurosawa, T.
    Ueda, K.
    Nagato, K.
    Saida, T.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 928 - 929
  • [50] Long-term efficacy and safety of subcutaneous garadacimab for prophylaxis of hereditary angioedema attacks: Results from a multicentre phase 3 study and open-label extension
    Magerl, M.
    Reshef, A.
    Farkas, H.
    Li, H. H.
    Jacobs, J. S.
    Bernstein, J.
    Yang, W.
    Stroes, E. S.
    Ohsawa, I.
    Tachdjian, R.
    Manning, M. E.
    Lumry, W. R.
    Saguer, I. Martinez
    Aygoeren-Puersuen, E.
    Ritchie, B.
    Sussman, G. L.
    Anderson, J.
    Kawahata, K.
    Suzuki, Y.
    Staubach, P.
    Treudler, R.
    Feuersenger, H.
    Jacobs, I.
    Craig, T. J.
    ALLERGY, 2023, 78 : 115 - 117
12345